Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 1, 2006, Pages 210-219

  Olsen, Keith M ^a   Gentry Nielsen, Martha ^b,c,d   Yue, Mei ^c   Snitily, Mary U ^c   Preheim, Laurel C ^b,c,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; LEVOFLOXACIN; MOXIFLOXACIN; PHOSPHATE BUFFERED SALINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; CELL CULTURE; CONTROLLED STUDY; DIET; DRUG ALCOHOL INTERACTION; DRUG EFFICACY; IMMUNE DEFICIENCY; LEUKOCYTE COUNT; LOBAR PNEUMONIA; LUNG LAVAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; ETHANOL; FLUOROQUINOLONES; LEUKOCYTE COUNT; PNEUMONIA, PNEUMOCOCCAL; RATS; RATS, SPRAGUE-DAWLEY; STREPTOCOCCUS PNEUMONIAE;

EID: 29944434727     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.1.210-219.2006     Document Type: Article

References (61)

1. American Thoracic Society. 2001. Guidelines for the management of adults with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 163:1730-1754.
2. Andrews, J. M., D. Honebourne, N. P. Brenwald, D. Bannerjee, M. Iredale, B. Cunningham, and R. Wise. 1997. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 39:797-802.
3. Baldwin, D. R., D. Honeybourne, and R. Wise. 1992. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob. Agents Chemother. 36:1171-1175.
4. Barman Balfour J. A., and L. R. Wiseman. 1999. Moxifloxacin. Drugs 57:363-373.
5. Bartlett, J. G., S. F. Dowell, L. A. Mandell, T. M. File, Jr., D. M. Musher, and M. J. Fine. 2000. Update of practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 31:347-382.
6. Bergogne-Bérézin, E. 2002. Clinical role of protein binding of quinolones. Clin. Pharmacokinet. 41:741-750.
7. Berry, V., R. Page, J. Satterfield, C. Singley, C. R. Straub, and G. Woodnutt. 2000. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection. J. Antimicrob. Chemother. 45(Suppl. S1):79-85.
8. Blondeau, J. M. 1999. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J. Antimicrob. Chemother. 43(Suppl. B):1-11.
9. Brighty, K. E., and T. D. Gootz. 1997. The chemistry and biological profile of trovafloxacin. J. Antimicrob. Chemother. 39(Suppl. B):1-14.
10. Buxbaum, A., U. Straschil, C. Moser, W. Graninger, A. Georgopoulos, et al. 1999. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. J. Antimicrob. Chemother. 43(Suppl. B):13-18.
11. Capitano, B., H. M. Mattoes, E. Shore, A. O'Brien, C. Sutherland, and D. P. Nicolau. 2004. Steady state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125:965-973.
12. Cheng, F. C., T. R. Tsai, Y. F. Chen, L. C. Hung, and T. H. Tsai. 2002. Pharmacokinetic study of levofloxacin in rat blood and bile by microdialysis and high-performance liquid chromatography. J. Chromatogr. A 961:131-136.
13. Cooper, B., and E. G. Maderazo. 1988. Alcohol abuse and impaired immunity. Infect. Med. 5:479-487.
14. Culley, C. M., M. K. Lacy, N. Klutman, and B. Edwards. 2001. Moxifloxacin: clinical efficacy and safety. Am. J. Health-Syst. Pharm. 58:379-388.
15. Davis, R., and H. M. Bryson. 1994. Levofloxacin: a review of its antibacterial activity, pharmacokinetics, and therapeutic efficacy. Drugs 47:677-700.
16. DeCarli, M., and C. S. Lieber. 1967. Fatty liver in the rat after prolonged intake of ethanol with a nutritionally adequate new liquid diet. J. Nutr. 91:331-336.
17. Dunbar, L. M., R. G. Wunderink, M. P. Habib, L. G. Smith, A. M. Tenneberg, M. M. Khashab, B. A. Wiesinger, J. X. Xiang, N. Zadeikis, and J. B. Kahn. 2003. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 37:752-760.
18. Efthymiopoulos, C., S. L. Bramer, A. Maroli, J. F. Flaherty, Jr., E. Wolfe, N. Bass, and K. Somberg. 1997. Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction. Clin. Pharmacokinet. 33(Suppl. 1):25-31.
19. Eliopoulos G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering. Jr. 1993. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37:366-370.
20. Ellbogen, M. H., K. M. Olsen, M. J. Gentry-Nielsen, and L. C. Preheim. 2003. Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J. Antimicrob. Chemother. 51:83-91.
21. File, T. M., Jr. 2003. Community acquired pneumonia. Lancet 361:1991-2001.
22. Gentry, M. J., and L. C. Preheim. 1999. Models of pneumonia in ethanol-treated rats, p. 501-507. In O. Zak and M. Sande (ed.), Handbook of animal models of infection. Academic Press, Inc., San Diego, Calif.
23. Gentry, M. J., M. U. Snitily, and L. C. Preheim. 1996. Decreased uptake and killing of Streptococcus pneumoniae within the lungs of cirrhotic rats. Immunol. Infect. Dis. 6:43-47.
24. Gentry-Nielsen, M. J., K. M. Olsen, and L. C. Preheim. 2002. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob. Agents Chemother. 46:1345-1351.
25. Hook, E. W., C. A. Horton, and D. R. Schaberg. 1983. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 249:1055-1057.
26. Jareo, P. W., L. C. Preheim, P. D. Lister, and M. J. Gentry. 1995. The effect of ethanol ingestion on killing of Streptococcus pneumoniae, Staphylococcus aureus, and Staphylococcus epidermidis rat neutrophils. Alcohol Alcoholism 30:311-318.
27. Jareo, P. W., L. C. Preheim, and M. J. Gentry. 1996. Ethanol ingestion impairs neutrophil bactericidal mechanisms against Streptococcus pneumoniae. Alcohol. Clin. Exp. Res. 20:1646-1652.
28. Jorgensen, J. H., L. M. Weigel, M. J. Ferraro, J. M. Swenson, and F. C. Tenover. 1999. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob. Agents Chemother. 43:329-334.
29. Kapp, A., and G. Zeck-Kapp. 1990. Activation of the oxidative metabolism in human polymorphonuclear neutrophilic granulocytcs: the role of immunomodulating cytokines. J. Investig. Dermatol. 95:94S-99S.
30. Kim, Y. S., Q. Liu, L. L. Chow, and M. G. Täuber. 1997. Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1186-1189.
31. Krasemann, C., J. Meyer, and G. Tillotson. 2001. Evaluation of the clinical microbiology profile of moxifloxacin. Clin. Infect. Dis. 32(Suppl. 1):S51-S63.
32. Leggett, J. E., B. Fantin, S. Ebert, K. Totsuka, B. Vogelman, W. Calame, H. Mattie, and W. A. Craig. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh infection models. J. Infect. Dis. 159:281-292.
33. Lieber, C. S. 1991. Hepatic, metabolic and toxic effects of ethanol: 1991 update. Alcohol. Clin. Exp. Res. 15:573-592.
34. Litwin, S. D. 1990. Alcohol research in the Veterans Administration: a success story. Alcohol. Clin. Exp. Res. 14:787-788.
35. Mandell, L. A., J. G. Bartlett, S. F. Dowell, T. M. File, Jr., D. M. Musher, and C. Whitney. 2003. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37:1405-1433.
36. Mellencamp, M. A., and L. C. Preheim. 1991. Pneumococcal pneumonia in a rat model of cirrhosis: effects of cirrhosis on pulmonary defense mechanisms against Streptococcus pneumoniae. J. Infect. Dis. 163:102-108.
37. Mufson, E. O., D. M. Kruss, R. E. Wasil, and W. I. Metzger. 1974. Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Arch. Intern. Med. 134:505-510.
38. Nicolau, D. P., H. M. Mattoes, M. Banevicius, D. Xuan, and C. H. Nightingale. 2003. Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model. Antimicrob. Agents Chemother. 47:1630-1635.
39. Olsen, K. M., G. S. San Pedro, L. P. Gann, P. O. Gubbins, D. M. Halinski, and G. D. Campbell. 1996. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob. Agents Chemother. 40:2582-2585.
40. Perry, A. C., B. Prpa, M. S. Rouse, K. E. Piper, A. D. Hanssen, J. M. Steckelberg, and R. Patel. 2003. Levofloxacin and trovafloxacin inhibition of experimental fracture-healing. Clin. Orthop. 414:95-100.
41. Preheim, L. C., and M. J. Gentry. 1996. Infection in the alcoholic, p. 308-311. In D. Schlossberg (ed.), Current therapy of infectious disease. The C.V. Mosby Co., St. Louis, Mo.
42. Preheim, L. C., M. J. Gentry, and M. U. Snitily. 1991. Pulmonary recruitment, adherence, and chemotaxis of neutrophils in a rat model of cirrhosis and pneumococcal pneumonia. J. Infect. Dis. 164:1203-1206.
43. Prehelm, L. C., M. A. Mellencamp, M. U. Snitily, and M. J. Gentry. 1992. Effect of cirrhosis on the production and efficacy of pneumococcal capsular antibody in a rat model. Am. Rev. Respir. Dis. 146:1054-1058.
44. Preheim, L. C., M. U. Snitily, and M. J. Gentry. 1996. Effects of granulocyte colony-stimulating factor in cirrhotic rats with pneumococcal pneumonia. J. Infect. Dis. 174:225-228.
45. Preheim, L. C., K. M. Olsen, M. Yue, M. U. Snitily, and M. J. Gentry-Nielsen. 2005. Effect of cirrhosis on antibiotic efficacy in a rat model of pneumococcal pneumonia. Diagn. Microbiol. Infect. Dis. 51:103-111.
46. Preheim, L. C., K. M. Olsen, M. Yue, M. U. Snitily, and M. J. Gentry. 1999. Ethanol feeding does not affect the efficacy or pharmacokinetics of azithromycin, trovafloxacin, or ceftriaxone in a rat model of pneumococcal pneumonia. Alcohol. Clin. Exp. Res. 23:842-849.
47. Renard, S. I., G. Basset, D. Lecossier, K. M. O'Donnell, P. Pinkston, P. G. Martin, and R. G. Crystal. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as a marker of dilution. J. Appl. Physiol. 69:532-538.
48. Sahm, D. F., C. Thornsberry, M. E. Jones, R. S. Blosser, I. A. Critchley, A. T. Evangelista, and J. A. Karlowsky. 2002. Correlations of antimicrobial resistance among Streptococcus pneumoniae in the United States: 2001-2002 TRUST surveillance, abstr. C2-1640. Abstr. Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
49. Scheid, W. M. 2003. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg. Infect. Dis. 9:1-9.
50. Siefert, H. M., C. Kohlsdorfer, W. Steinke, and A. Witt. 1999. Pharmacokinetics of the 8-metheoxyquinolone, moxifloxacin: tissue distribution in male rats. J. Antimicrob. Chemother. 43(Suppl. B):61-67.
51. Snitily, M. U., M. J. Gentry, M. A. Mellencamp, and L. C. Preheim. 1991. A simple method for collection of blood from the rat foot. Lab. Anim. Sci. 41:285-287.
52. Teng, R., G. Girard, T. D. Gootz, T. Foulds, and T. E. Liston. 1996. Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. Antimicrob. Agents Chemother. 40:561-566.
53. Teng, R., T. G. Tensfeldt, T. E. Liston, and G. Foulds. 1996. Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reverse-phase high performance liquid chromatography. J. Chromatogr. B 675:53-59.
54. Thomson, K. S., S. A. Chartrand, C. C. Sanders, and S. L. Block. 1997. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:478-480.
55. Vaudaux, P., P. Francois, C. Bisognano, J. Schrenzel, and D. P. Lew. 2002. Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46:1503-1509.
56. Vincent, J., R. Teng, B. A. Baris, S. A. Willavize, R. J. Polzer, and H. L. Friedman. 1997. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous does of the pro-drug, alatrofloxacin. J. Antimicrob. Chemother. 39(Suppl. B):75-80.
57. Weinberg, E. D. 1990. Cellular iron metabolism in health and disease. Drug Metab. Rev. 22:531-579.
58. Wilcox, M., A. Kervitsky, L. C. Watter, and T. E. King, Jr. 1988. Quantification of cells recovered by bronchoalveolar lavage. Am. Rev. Respir. Dis. 138:74-80.
59. Wright, D. H., G. H. Brown, M. L. Peterson, and J. C. Rotschafer. 2000. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46:669-683.
60. Wright, D. H., V. K. Herman, F. N. Konstantinides, and J. C. Rotschafer. 1998. Determination of quinolones antibiotics in growth media by reversed-phase high performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 709:97-104.
61. Yu, V. L., C. C. Chiou, C. Feldman, A. Ortqvist, J. Rello, A. J. Morris, L. M. Baddour, C. M. Luna, D. R. Snydman, M. Ip, W. C. Ko, B. F. Chedid, A. Andremont, and K. P. Klugman. 2003. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin. Infect. Dis. 37:230-237.